• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer

    2/10/22 4:30:00 PM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLLS alert in real time by email

    NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the appointment of Bing C. Wang, PhD, MBA, as Chief Financial Officer and member of Cellectis' executive committee.

    Dr. Wang is a highly accomplished biotechnology executive who brings extensive global finance experience in the biotechnology industry including a background with global public companies in corporate finance, mergers and acquisitions, operations management systems, and financial planning and analysis. He joins Cellectis to oversee the company's global finance team reporting directly to Chief Executive Officer, André Choulika, PhD.

    Prior to joining Cellectis, Dr. Wang was most recently the Chief Executive Officer and Director of Refuge Biotechnologies Inc., a cell therapy immune-oncology biotechnology company leveraging synthetic biology and gene engineering, which he co-founded following nearly a decade of healthcare investment banking experience. Prior to his tenure at Refuge, Dr. Wang worked in healthcare investment banking at Barclays Capital Inc. and Citigroup Global Markets Inc.

    At Barclay's, Dr. Wang served as director of healthcare investment banking where he acted as strategic financial advisor and helped raised capital for companies in the healthcare industry. Dr. Wang had also served as Board Director at KBP Biosciences, a clinical-stage biotechnology company. He is currently on the advisory board of the Healthcare and Pharmaceutical Management Program at Columbia Business School.

    "Bing's extensive experience in global finance and operations, as well as his track record financing clinical-stage biotech companies, will be critical as we will enter our next stage of development of our clinical trials," said André Choulika, PhD, Chief Executive Officer. "On behalf of the entire Cellectis team, I welcome Bing and look forward to his contributions."

    "I'm thrilled to be joining a company that has strong and integrated capabilities in clinical development, manufacturing, translational science, and a well validated gene editing platform. As a 20-year cancer survivor, I look forward to joining the Cellectis team, to contribute to the company's mission in developing durable and off-the-shelf cancer therapies," said Dr. Wang. 

    Dr. Wang holds a Bachelor of Science in Applied Physics from Columbia University, MA and Ph.D. in Electrical Engineering from Princeton University, and MBA from Columbia Business School.

    About Cellectis 

    Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR-T cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.  

    Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).  

    For more information, visit www.cellectis.com     

    Follow Cellectis on social media: @cellectis, LinkedIn and YouTube. 

    For further information, please contact: 

    Media contacts: 

    Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, [email protected]    

    Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300 

    Investor Relation contact: 

    Arthur Stril, Chief Business Officer, +33 (0)1 81 69 16 69, [email protected] 

    Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577, [email protected]

     Forward-looking Statements  

    This presentation contains "forward-looking" statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "at this time," "anticipate," "believe," "expect," "on track," "plan," "scheduled," and "will," or the negative of these and similar expressions. These forward-looking statements, which are based on our management's current expectations and assumptions and on information currently available to management, include statements about our research and development projects and priorities, our pre-clinical project development efforts, the timing and progress of clinical trials (including with respect to patient enrollment and follow-up), the timing of our presentation of data, the adequacy of our supply of clinical vials, the timing of completion of construction of our Raleigh, North Carolina manufacturing facility, and operational capabilities at our manufacturing facilities, and the sufficiency of cash to fund operations. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development as well as the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2020 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

     

    Attachment

    • 20220210_Press_release_CFO_Appointment_PW_V2_Bing comments


    Primary Logo

    Get the next $CLLS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CLLS

    DatePrice TargetRatingAnalyst
    3/17/2023$6.00Buy
    Bryan Garnier
    5/18/2022$10.00Neutral → Outperform
    Robert W. Baird
    1/6/2022$16.00Overweight → Equal-Weight
    Wells Fargo
    11/30/2021$20.00Mkt Outperform
    JMP Securities
    11/8/2021Outperform → Mkt Perform
    William Blair
    10/8/2021$39.00 → $10.00Outperform → Neutral
    Baird
    10/8/2021$39.00 → $10.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $CLLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025

      NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis ((Euronext Growth: ALCLS, NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which approximately 57% of voting rights were exercised, resolutions 1 through 23 and resolutions 25 and 26 were adopted, while resolution 24 was rejected, consistent with the recommendations of the board of directors. The Cellectis shareholders' meeting appointed Mr. André Muller as a member of the Company's Board o

      6/26/25 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025

      NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice convening the annual general meeting stating the detailed agenda and modalities of participation in the meeting and the report of the board of directors to the shareholders meeting are available on the Cellectis website: https://www.cellectis.com/en/investors/general-meetings/ About Cellectis      Cell

      5/21/25 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis Reports Financial Results for the First Quarter 2025

      Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderCellectis will present novel non-viral gene editing and base editing research at the 2025 ASGCT annual meetingCash position of $246 million as of March 31, 20251 provides runway into H2 2027 NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Ce

      5/12/25 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLLS
    SEC Filings

    See more
    • SEC Form F-3 filed by Cellectis S.A.

      F-3 - Cellectis S.A. (0001627281) (Filer)

      7/2/25 4:16:54 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Cellectis S.A.

      6-K - Cellectis S.A. (0001627281) (Filer)

      6/26/25 4:35:04 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Cellectis S.A.

      6-K - Cellectis S.A. (0001627281) (Filer)

      6/26/25 4:30:04 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bryan Garnier initiated coverage on Cellectis with a new price target

      Bryan Garnier initiated coverage of Cellectis with a rating of Buy and set a new price target of $6.00

      3/17/23 9:01:09 AM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Cellectis from Neutral to Outperform and set a new price target of $10.00

      5/18/22 7:11:44 AM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Cellectis from Overweight to Equal-Weight and set a new price target of $16.00

      1/6/22 5:50:31 AM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLLS
    Leadership Updates

    Live Leadership Updates

    See more
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

      UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderAppointed Adrian Kilcoyne, M.D., MPH, MBA, an industry leader in the advancement of cell therapy treatment, as Chief Medical OfficerCash position of $264 million as of September 30, 20241; cash runway projection into 2027Conference call scheduled for 8:00 am ET / 2:00 pm CET on November 5, 2024 NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company

      11/4/24 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

      NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately. "We're thrilled to welcome Dr. Kilcoyne to Cellectis. He is a strategic, forward-thinking drug developer who is passionate about delivering life-saving therapies to patients. His clinical vision and proven leadership, as well as his extensive experience, will strengthen our clinical development efforts as we advance our product pipeline of next-generation

      8/7/24 2:00:00 AM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLLS
    Financials

    Live finance-specific insights

    See more
    • Cellectis Reports Financial Results for the First Quarter 2025

      Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderCellectis will present novel non-viral gene editing and base editing research at the 2025 ASGCT annual meetingCash position of $246 million as of March 31, 20251 provides runway into H2 2027 NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Ce

      5/12/25 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis to Report First Quarter Financial Results on May 12, 2025

      NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis' website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at [email protected]      About Cellectis  Ce

      5/6/25 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

      ○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL. ○ UCART20x22 Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025. ○ AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorder. ○ Cash position of $264 million as of December 31, 20241 provides runway in

      3/13/25 6:07:50 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Cellectis S.A. (Amendment)

      SC 13D/A - Cellectis S.A. (0001627281) (Subject)

      5/21/24 4:19:05 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cellectis S.A. (Amendment)

      SC 13G/A - Cellectis S.A. (0001627281) (Subject)

      2/14/24 5:07:22 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cellectis S.A. (Amendment)

      SC 13G/A - Cellectis S.A. (0001627281) (Subject)

      2/14/24 2:24:22 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care